Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 75 25 PEN versus NOVOLOG MIX 70 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 75 25 PEN versus NOVOLOG MIX 70 30.
HUMALOG MIX 75/25 PEN vs NOVOLOG MIX 70/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin analog with intermediate-acting insulin (insulin lispro protamine suspension) and rapid-acting insulin (insulin lispro). Binds to insulin receptors, activating glucose uptake, glycogen synthesis, and lipogenesis, while inhibiting gluconeogenesis and ketogenesis.
Biphasic insulin analog combining rapid-acting insulin aspart and intermediate-acting protamine-crystallized insulin aspart, which lowers blood glucose by stimulating peripheral glucose uptake and inhibiting hepatic glucose production.
Subcutaneous injection. Individualized based on metabolic needs. Typical total daily insulin dose: 0.5-1 unit/kg/day divided, with Humalog Mix 75/25 given 15 minutes before meals. Starting dose: 0.2-0.3 unit/kg/day for type 1 diabetes; 0.3-0.5 unit/kg/day for type 2 diabetes. Administer twice daily: before breakfast and before dinner. Dose adjustments based on blood glucose monitoring.
Subcutaneous injection only. Typical total daily insulin dose ranges from 0.5 to 1.0 units/kg/day divided into two or three injections. Administer twice daily, with each dose given within 15 minutes before meals. Dose individualization based on glycemic targets and previous insulin regimen is required.
None Documented
None Documented
Insulin lispro protamine: 13-16 hours (intermediate component); Insulin lispro: 1-2 hours (rapid component). Clinical context: Steady state achieved after 2-4 days of dosing.
Insulin aspart (free component): ~1-2 hours; protamine-crystallized component: ~8-10 hours. Clinical context: Duration of action up to 24 hours due to the intermediate-acting component.
Renal: 30-80% (protamine-insulin complex clearance); Hepatic: 10-20% (degradation by insulinase); Fecal: <1%
Renal: 30-80% of dose excreted unchanged in urine for insulin aspart; for protamine-crystallized component, metabolism and renal elimination also occur. Biliary/fecal: Minor.
Category C
Category C
Insulin Analog
Insulin Analog